<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544804</url>
  </required_header>
  <id_info>
    <org_study_id>UCSF-077518</org_study_id>
    <nct_id>NCT00544804</nct_id>
  </id_info>
  <brief_title>Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2</brief_title>
  <official_title>A Phase I Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib in&#xD;
      treating patients with advanced or metastatic breast cancer that overexpresses HER2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum tolerated dose (MTD) of high-dose lapatinib ditosylate in&#xD;
           patients with HER2-overexpressing advanced or metastatic breast cancer.&#xD;
&#xD;
        -  To determine the dose-limiting toxicity of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine whether tumor HER2 can be completely inactivated by lapatinib ditosylate at&#xD;
           its MTD in the 5-day schedule.&#xD;
&#xD;
        -  To determine whether the total inactivation of HER2 decreases cardiac ejection fraction.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to dose level.&#xD;
&#xD;
      Patients receive escalating doses of oral lapatinib ditosylate twice daily on days 1-5 until&#xD;
      the maximum tolerated dose is determined. Courses repeat every 2 weeks in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Some patients undergo tumor tissue and blood sample collection periodically for biological&#xD;
      and correlative studies. Samples are analyzed for evidence of cardiac injury, tumor target&#xD;
      lysis effects, and to determine if the lapatinib serum levels result in the inactivation of&#xD;
      tumor HER2 and HER3 kinase and oncogenic signaling.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of Lapatinib</measure>
    <time_frame>estimated to be 12 months</time_frame>
    <description>Dose Escalation of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Lapatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib ditosylate</intervention_name>
    <arm_group_label>Lapatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <arm_group_label>Lapatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
    <arm_group_label>Lapatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
               -  Advanced or metastatic disease&#xD;
&#xD;
               -  No effective curative therapy available&#xD;
&#xD;
          -  Bone-only disease allowed&#xD;
&#xD;
          -  Tumor HER2 overexpression&#xD;
&#xD;
               -  HER2 3+ expression by immunohistochemistry OR &gt; 2-fold (HER2 2+) gene&#xD;
                  amplification by fluorescence in situ hybridization&#xD;
&#xD;
          -  Evaluable disease&#xD;
&#xD;
               -  Measurable disease is not required&#xD;
&#xD;
          -  No progressive brain metastases&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000 cells/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 75,000 cells/mm^3&#xD;
&#xD;
          -  Total bilirubin normal&#xD;
&#xD;
          -  AST and ALT ≤ 3 x upper limits of normal (ULN) (≤ 5 x ULN with liver metastases)&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
          -  INR ≤ 1.5&#xD;
&#xD;
          -  Potassium normal&#xD;
&#xD;
          -  Magnesium normal&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception prior to and during study therapy&#xD;
&#xD;
          -  Cardiac ejection fraction ≥ 50%&#xD;
&#xD;
          -  Consents to 2 tumor fine needle aspiration biopsies for biomarker analysis&#xD;
&#xD;
               -  Lung-only disease or sites otherwise deemed high-risk for biopsy, the requirement&#xD;
                  for biopsy will be waived&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of significant cardiac disease including any of the following:&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Symptomatic cardiac arrhythmias&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
          -  Uncontrolled prior lapatinib ditosylate therapy toxicity ≥ grade 2&#xD;
&#xD;
          -  Allergic reactions to IV contrast dye despite standard prophylaxis&#xD;
&#xD;
          -  History of malabsorption syndrome or disease significantly affecting gastrointestinal&#xD;
             function or major resection of the stomach or small bowel that could affect&#xD;
             absorption, distribution, metabolism, or excretion of study drug&#xD;
&#xD;
          -  Conditions that would impair the patient's ability to swallow and retain oral&#xD;
             medication&#xD;
&#xD;
          -  Concurrent disease or condition that would make the patient inappropriate for study&#xD;
             participation or would interfere with the patient's safety&#xD;
&#xD;
          -  Psychological, familial, sociological, or geographical conditions that do not permit&#xD;
             compliance with the protocol&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Prior lapatinib ditosylate or trastuzumab allowed&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent chemotherapy or investigational&#xD;
             anticancer agents&#xD;
&#xD;
          -  At least 2 weeks since prior and no concurrent hormonal therapy&#xD;
&#xD;
          -  At least 2 weeks since prior and no concurrent lapatinib ditosylate prohibited&#xD;
             medications, including CYP3A4 inhibitors or inducers, all herbal supplements, and&#xD;
             gastric pH modifiers&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No aspirin or plavix therapy within 7 days prior to tumor biopsy&#xD;
&#xD;
          -  No concurrent coumadin&#xD;
&#xD;
               -  Low molecular weight heparin allowed provided it can be held at least 24 hours&#xD;
                  prior to tumor biopsy&#xD;
&#xD;
          -  Concurrent gonadal suppression agents (i.e., Zoladex or Lupron) or palliative&#xD;
             bisphosphonates (i.e., Zometa) allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark M. Moasser, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10;32(14):1472-9. doi: 10.1200/JCO.2013.52.1161. Epub 2014 Apr 7.</citation>
    <PMID>24711549</PMID>
  </results_reference>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>October 13, 2007</study_first_submitted>
  <study_first_submitted_qc>October 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <last_update_submitted>July 1, 2014</last_update_submitted>
  <last_update_submitted_qc>July 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>bone metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

